Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in advancing the clinical pipeline at Aeglea as they work to unlock the potential of engineered human enzymes to develop treatment options for patients with rare genetic diseases. The Chase Group is proud to connect this patient focused company with high caliber talent and wish Aeglea the best of success.
Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership with The Chase Group, Inc.
Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in advancing the clinical pipeline at Aeglea as they work to unlock the potential of engineered human enzymes to develop treatment options for patients with rare genetic diseases. The Chase Group is proud to connect this patient focused company with high caliber talent and wish Aeglea the best of success.
Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership with The Chase Group, Inc.
Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in…
Eli Lilly Welcomes New Vice President, Immuno-Oncology Global & US Medical Affairs
The Chase Group is pleased to announce the placement of the Vice President, Immuno-Oncology Global & US Medical Affairs for Eli Lilly. The successful candidate…
The Chase Group Places VP of Clinical Development and Pharmacovigilance at Marinus Pharmaceuticals
The Chase Group is pleased to continue partnership with Marinus in building their leadership team with the recent placement of the Vice President of Clinical…-
The Chase Group Secures the Vice President, US and Global Medical Affairs for Eli Lilly
The Chase Group is pleased to announce the successful completion of the Vice President, US and Global Medical Affairs at Eli Lilly. The new Vice… 
Ionis Pharmaceuticals Secures Associate Director, Investor Relations
The Chase Group is pleased to announce our latest placement for Ionis Pharmaceuticals. Due to exciting organizational growth, Ionis welcomes a new Associate Director, Investor…
The Chase Group Secures the Vice President, Global Head of Data Sciences for Genmab
The Chase Group is pleased to announce the successful completion of the Vice President, Global Head of Data Sciences search at Genmab. A scientist with…